DEF: T Stamp Inc. Sets 2025 Annual Meeting, Seeks Key Approvals

T Stamp Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 30, 2025, seeking approval for director elections, auditor ratification, and a significant warrant issuance.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Tuesday, December 30, 2025, at 9:00 a.m. Eastern Standard Time.
• Stockholders will vote on three key proposals: (1) the election of two Class III directors to serve until the 2028 Annual Meeting, (2) the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and (3) the ratification of the issuance of Private Placement Warrants (Series A and Series B) to Armistice Capital Master Fund Ltd.
• The Private Placement Warrants are exercisable for up to 648,148 shares of Class A Common Stock at an exercise price of $8.10 per share, issued pursuant to a Securities Purchase Agreement dated December 5, 2024 (Armistice SPA).
• The Armistice SPA offering, which closed on December 6, 2024, raised gross proceeds of approximately $3.0 million before deducting fees.
• If all Private Placement Warrants are exercised for cash, the company expects to receive additional gross proceeds of approximately $5,249,993.
• Previous attempts to obtain shareholder approval for the Armistice SPA and warrant issuance at special meetings on February 7, 2025, and May 15, 2025, failed due to a lack of quorum.
• The company's primary use of net proceeds from the Armistice SPA is for working capital, capital expenditures, and other general corporate purposes.
• As of the record date of November 5, 2025, 4,675,833 shares of Class A Common Stock were issued and outstanding.
• The Board of Directors consists of seven members, with 28.57% being female as of November 12, 2025, and four directors deemed independent under Nasdaq rules.

Sentiment

Score: 4

Explanation: The filing outlines necessary corporate governance actions and a significant financing event. While the potential for additional capital is positive, the repeated failure to secure shareholder approval for the warrant issuance and the resulting dilution are notable concerns, indicating operational challenges and potential shareholder friction. The need for ongoing meetings to secure approval adds to uncertainty and cost.

Positives

• The company is seeking ratification for a capital raise that could bring in an additional $5.25 million if all Private Placement Warrants are exercised, providing significant working capital.
• The Board is actively reviewing its composition and striving for diversity, with 28.57% female directors as of November 12, 2025.
• Established Audit, Compensation, and Nominating & Corporate Governance Committees are in place, aligning with good corporate governance practices.
• Lance Wilson, instrumental in the company's Nasdaq listing, was appointed Chief Financial Officer in January 2025, strengthening the financial reporting function.

Negatives

• Previous attempts to obtain shareholder approval for the Armistice SPA and warrant issuance failed due to a lack of quorum, indicating potential shareholder apathy or resistance to the transaction.
• Failure to approve Proposal 3 at the upcoming Annual Meeting would prevent the company from receiving up to $5.25 million in potential proceeds from warrant exercises and would incur substantial additional costs for future meetings.
• Approval of Proposal 3 will result in dilution for existing stockholders, as an additional 648,148 shares of Class A Common Stock would be added to the outstanding capital stock upon full exercise of the warrants.
• The potential sale of shares issued upon warrant exercise into the public market could materially and adversely affect the market price of Class A Common Stock.

Risks

• Failure to obtain shareholder approval for Proposal 3 could prevent the exercise of Private Placement Warrants, leading to a loss of up to $5.25 million in potential gross proceeds and incurring substantial additional meeting costs.
• Existing stockholders will suffer dilution in their ownership interests upon the issuance of the 648,148 shares from the exercise of the Private Placement Warrants.
• The sale of shares from warrant exercises into the public market could materially and adversely affect the market price of Class A Common Stock.
• Operational, economic, financial, legal, regulatory, and competitive risks are inherent to the business, as detailed in the Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company intends to use the net proceeds from the Armistice SPA for working capital, capital expenditures, and general corporate purposes. It is contractually obligated to hold meetings every 90 days to seek shareholder approval for the Private Placement Warrants until approval is obtained or the warrants are no longer outstanding.

Management Comments

• "We cordially invite you to attend the 2025 Annual Meeting of Stockholders of T Stamp Inc. dba Trust Stamp."
• "Your vote is important. We hope you will attend the virtual Annual Meeting. We encourage you to review the proxy materials and vote as soon as possible."
• "The Company's primary use of the net proceeds from the Armistice SPA is to support its working capital requirements, along with making capital expenditures as necessary and other general corporate purposes."

Industry Context

This filing is a standard proxy statement, primarily focused on corporate governance and a specific financing event. It highlights the company's ongoing need for capital to support operations and growth, a common characteristic for companies in the technology and cybersecurity sectors. The compliance with Nasdaq listing rules for shareholder approval of significant transactions is a standard regulatory requirement for publicly traded entities.

Comparison to Industry Standards

• The company's board diversity, with 28.57% female directors, indicates an effort towards modern corporate governance standards, though specific industry benchmarks for this metric are not provided in the filing.
• The classified board structure is a common governance model, although some investors and governance advocates prefer declassified boards for increased accountability.
• The requirement for shareholder approval for the warrant issuance under Nasdaq Listing Rule 5635(d) is a standard regulatory compliance for transactions involving the issuance of securities exceeding 20% of outstanding common stock.
• The engagement of CBIZ CPAs P.C. as an independent auditor since 2022 is a standard practice for public companies to ensure financial statement integrity.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not aware of any of its directors currently being subject to any litigation, nor is it aware of any pending or threatened legal actions against its directors.

Related Party Transactions

• **QID Technologies LLC**: On November 12, 2024, the Company formed QID Technologies LLC with Qenta. On January 1, 2025, the Company entered into a Master Technology Service Agreement (MTSA) with QID to provide technical services for an initial minimum payment of $100,000 per month, not to exceed $300,000 per month without mutual agreement. The Company owns 10% equity in QID but is not involved in management. Qenta and DQI Holdings Inc. (a 5% Trust Stamp holder) have a common owner, making them related parties.
• **Vital4Data, Inc.**: On November 15, 2020, the Company entered into a Mutual Channel Agreement with Vital4Data, Inc., where one of Trust Stamp's directors serves as CEO. Vital4Data, Inc. acts as a non-exclusive sales representative, earning commissions (20% first year, 10% second, 5% third). No commissions earned or expensed as of June 30, 2025, and December 31, 2024.
• **CyberFish**: On April 17, 2025, the Company entered into a Channel Partnership Agreement with CyberFish, where director Berta Pappenheim serves as CEO. Trust Stamp sells CyberFish services to its clients, earning a 30% commission on net revenue. No commissions earned to date as of June 30, 2025, and December 31, 2024.

Stakeholder Impact

• **Shareholders**: Will be impacted by the outcome of the votes, particularly the potential dilution from warrant exercises if Proposal 3 is approved. Failure to approve Proposal 3 could lead to a lack of capital and ongoing meeting costs.
• **Management/Employees**: Compensation includes base salary and stock awards, aligning their interests with company performance and retention.
• **Creditors/Investors**: The successful ratification and exercise of warrants could provide significant capital, potentially improving the company's financial position and reducing perceived risk. Conversely, failure could signal financial instability.
• **Customers**: The use of proceeds for working capital and capital expenditures could support continued product development and service delivery, potentially enhancing customer experience and offerings.

Next Steps

• Stockholders are to vote on director elections, auditor ratification, and Private Placement Warrants issuance at the Annual Meeting on December 30, 2025.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K within four business days.
• If Proposal 3 is not approved, the company must call another meeting within 90 days to seek shareholder approval for the Private Placement Warrants.
• The company is required to keep the registration statement for the resale of shares from Private Placement Warrants effective until no investor owns them.

Key Dates

Recommendation

The company is addressing critical corporate governance matters and seeking to finalize a significant capital raise that could provide substantial working capital. However, the repeated failure to secure shareholder approval for the warrant issuance due to a lack of quorum is a red flag, indicating potential shareholder disengagement or concerns. While the potential for additional capital is positive, the associated dilution and the uncertainty surrounding shareholder approval warrant a cautious 'hold' stance until the outcome of the Annual Meeting and the company's ability to execute its financing strategy are clearer. The related party transactions also warrant careful monitoring.

Keywords

T Stamp Inc., Trust Stamp, DEF 14A, Proxy Statement, Annual Meeting, Stockholder Vote, Director Election, Auditor Ratification, Private Placement Warrants, Armistice SPA, Nasdaq Listing Rule 5635(d), Capital Raise, Dilution, Corporate Governance, CBIZ CPAs, Financial Reporting, Cybersecurity, Identity Verification